None
EN
US Judge Partly Refuses to Dismiss Investor Fraud Suit Against Novo Nordisk Over CagriSema
['Sheeba Farhat', 'Written']
Medical News, Health News Latest, Medical News Today - Medical Dialogues |
Novo Nordisk had no immediate comment.
Novo Nordisk's U.S. headquarters are in Plainsboro, New Jersey.
CagriSema combined semaglutide, the active ingredient in Novo Nordisk's Wegovy, with the molecule cagrilintide, which mimics the pancreatic hormone amylin.
Novo Nordisk sued Eli Lilly on July 21, accusing it of falsely advertising Zepbound and its diabetes treatment Mounjaro by comparing higher doses of those products with lower doses of Novo Nordisk's Wegovy and Ozempic.
A federal judge in Trenton will consider Novo Nordisk's request for a preliminary injunction to halt Eli Lilly's nationwide ads at an August 27 hearing.